Sanofi: Setbacks with Tolebrutinib weigh on the stock!

Sanofi has faced a setback with its MS program, realigning market expectations regarding the short-term development of its pipeline. At the center is the drug Tolebrutinib, which had previously been seen as one of the key hopes in the neurological portfolio. Delays in the regulatory process and disappointing study data have weighed on the stock, refocusing investors' attention on the dependence on individual development projects. FDA decision on Tolebrutinib not expected until the end of Q1 According to the company, the US Food and Drug Administration...